Giri Diagnostic Kits And Reagents Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 175.17%
(FY 2023)
- Profit -49.40%
(FY 2023)
- Ebitda -65.42%
(FY 2023)
- Net Worth -54.97%
(FY 2023)
- Total Assets -3.85%
(FY 2023)
About Giri Diagnostic Kits And Reagents
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Narendar Goswami and Brij Giri serve as directors at the Company.
- CIN/LLPIN
U51397UP2010PTC042461
- Company No.
042461
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Nov 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Varanasi, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Giri Diagnostic Kits And Reagents Private Limited offer?
Giri Diagnostic Kits And Reagents Private Limited offers a wide range of products and services, including Rapid Test Kit, Diagnostic Test Kit, Clinical Reagents, Diagnostic Reagents, IVDs & Analyzers, Biochemistry Analyzer, Hematology Analyzers, Medical Laboratory Instruments, Pathology Lab Equipments, Sexual Wellness Products.
Who are the key members and board of directors at Giri Diagnostic Kits And Reagents?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendar Goswami  | Director | 18-Apr-2017 | Current |
Brij Giri  | Director | 02-Nov-2010 | Current |
Financial Performance of Giri Diagnostic Kits And Reagents.
Giri Diagnostic Kits And Reagents Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 175.17% increase. The company also saw a substantial fall in profitability, with a 49.4% decrease in profit. The company's net worth observed a substantial decline by a decrease of 54.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Giri Diagnostic Kits And Reagents?
In 2023, Giri Diagnostic Kits And Reagents had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Giri Diagnostic Kits And Reagents?
Unlock and access historical data on people associated with Giri Diagnostic Kits And Reagents, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Giri Diagnostic Kits And Reagents, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Giri Diagnostic Kits And Reagents's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
